New immunotherapy! Nektar's immunostimulatory therapy, IL-15 signal pathway activator nktr-255, has entered human clinical practice!

October 22, 2019 / BIOON / - nektar Therapeutics recently announced the launch of the first human phase I clinical study to evaluate nktr-255, an interleukin-15 (IL-15) receptor agonist, which will evaluate nktr-255 as a single drug therapy for recurrent or refractory non Hodgkin's lymphoma (NHL) or multiple myeloma (mm), as well as nktr-255 and antibody dependent cell-mediated fine cell Multiple targeted antibody therapy combined with cytotoxic therapy (ADCC) for recurrent or refractory MM Nktr-255 aims to activate the IL-15 pathway, expand NK cells with superior natural killing function and promote the survival and expansion of memory CD8 + T cells without inducing inhibitory regulation of T cells One of the challenges in the treatment of cancer with targeted monoclonal antibodies is that cancer patients lack the key effector cells, such as NK cells, that are needed to interact with monoclonal antibodies In non clinical studies, nktr-255 has antitumor activity, enhances the proliferation and activation of NK cells in vivo, and provides sustained cytotoxic function In preclinical lymphoma model, daratumab single drug therapy was ineffective, while nktr-255 combined with daratumab treatment increased the number and activity of NK cells in bone marrow tissue, and enhanced ADCC mediated clearance of BMV tumor cells Nktr-255 is an IL-15 receptor agonist, which aims to activate the IL-15 pathway, expand NK cells without inducing inhibitory regulatory T cells, and promote the survival and expansion of memory CD8 + T cells Nktr-255 promotes the formation of long-term immune memory by optimizing its binding with il-15r α / IL-2R β γ receptor complex, which may lead to sustained anti-tumor immune response Nktr-255 is specially designed to overcome the challenge of recombinant IL-15, which can be rapidly removed from the body and must be administered frequently and in high doses However, its toxicity and convenience limit its use Wei Lin, senior vice president and R & D director of nektar therapeutics, said: "we are pleased to launch the first human clinical study of nktr-255, which shows promising and substantial antitumor activity in our preclinical study By increasing the number and activity of NK cells, nktr-255 has the potential to enhance the host anti-tumor response It can be used as a single drug or combined with tumor targeting antibodies, including daratumab and rituximab Original source: nektar therapeutics announcements initiation of first in human phase 1 clinical study of nktr-255, an IL-15 agonist, in results with relapsed or refactory non Hodgin lymphama or multiple myeloma